biostudies-literatureUnknown13Maiorano BAMetastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC.Frontiers in oncology1254906https://www.ebi.ac.uk/biostudies/studies/S-EPMC10535083biostudies-literatureEnfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?PMC10535083Maiello ERoviello GMaiorano BACatalano MfalseEnfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC.2023-01-01T00:00:00Z20232025-04-05T12:14:38.347Z2025-02-19T00:00:55.489ZS-EPMC105350833778118010.3389/fonc.2023.1254906